- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 6, 2021
P1/2, N=30, Not yet recruiting,
Supplemental data for this article is available online at https://doi.org/10.1080/07315724.2022.2032868 . Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=30, Not yet recruiting,
Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2024 Trial completion date: Feb 2019 --> Feb 2022 | Trial primary completion date: Feb 2019 --> Feb 2022
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial initiation date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 26, 2017
P1/2, N=30, Not yet recruiting,
Trial completion date: Feb 2019 --> Feb 2022 | Trial primary completion date: Feb 2019 --> Feb 2022 Initiation date: Feb 2017 --> Jun 2017
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 28, 2016
P1/2, N=30, Not yet recruiting,
Initiation date: Feb 2017 --> Jun 2017 Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
New P1/2 trial, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2016
P1/2, N=30, Not yet recruiting,
|
